A Transporter-Based Predictive ADME Platform

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$439,346.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43RR031474-01
Agency Tracking Number:
RR031474
Solicitation Year:
2010
Solicitation Topic Code:
NCRR
Solicitation Number:
PHS2010-2
Small Business Information
OPTIVIA BIOTECHNOLOGY, INC.
OPTIVIA BIOTECHNOLOGY, INC., 115 CONSTITUTION DR, STE 7, MENLO PARK, CA, 94025
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
804420029
Principal Investigator:
DALLAS BEDNARCZYK
() -
DBEDNARCZYK@OPTIVIABIO.COM
Business Contact:
YONG HUANG
(650) 324-3177
yhuang@optiviabio.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Desirable drug ADME (Absorption, Disposition, Metabolism and Elimination) properties are key determinants of a drug's to safety and efficacy. Unfortunately, poor ADME and Toxicity attributes have caused more drug failures than any other factors. There is a pressing need for better in vitro predictive ADME tools to augment the decade-old animal studies which do not always predict clinical results in the human. The overall goal of this project is to ascertain whether in vivo drug ADME properties could be explained and predicted based on drugs' in vitro interactions with transporter proteins, which have been demonstrated to play significant roles in every aspect of drug ADME, along with metabolic enzyme interaction and other drug physicochemical properties. The initial Phase I work will start with examining the roles of major liver transporters on hepatic disposition of drugs, through testing a panel of drugs against these transporters; novel in vitro models will be created for studying the effects of transporters-CYP interplay on hepatic drug metabolism; finally, correlations between in vitro data and clinical disposition and metabolism information will be established. Future study would extend the scope to other major tissues/organs with aims to explain and predict drug ADME properties and drug-drug interactions (DDI) based on in vitro transporter studies and other drug physicochemical properties. PUBLIC HEALTH RELEVANCE: Success of this project will benefit public health by facilitating discovery and development of drugs for treating various formidable diseases, particularly CNS diseases and cancer, through enhancing drug efficacy by increasing targeted drug delivery to diseased tissues, and through improving drug safety by reducing adverse drug effects due to unwanted tissue distribution and drug-drug interactions.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government